delfidiagnostics.comHealthcare / Digital HealthFounded: 2019Funding to Date: $326.47MM
Delfi Diagnostics is a biotechnology company with a mission to use its technology for early cancer detection. By developing AI and ML algorithms, Delfi Diagnostics offers predictive testing processes with the goal of maximizing patient survival rates. The company specializes in the detection of breast cancer and aims to help healthcare organizations minimize treatment toxicity with less-invasive treatments. Delfi Diagnostics was founded by Alessandro Leal and Victor Velculescu in 2019 and is headquartered in Baltimore, MD.
Funding Date | Share Class | Amount Raised | Price per Share | Post-Money Valuation | Key Investors | |
---|---|---|---|---|---|---|
07/18/2022 | Series B | $225MM | $xx.xx | $685.11MM | DFJ Growth, Eli Lilly and Company, Point72, Brown Advisory, Point Field Partners, Initiate Ventures, Open Field Capital, PTX Capital, Cowen Healthcare Investments, Foresite Capital, Menlo Ventures, OrbiMed, T. Rowe Price Associates, Northpond Ventures, Samsara BioCapital, Rock Springs Capital, AV8 Ventures, Illumina Ventures, Osage University Partners, Windham Venture Partners | |
Price per Share
$xx.xx
Shares Outstanding
46,434,241
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
DFJ Growth, Eli Lilly and Company, Point72, Brown Advisory, Point Field Partners, Initiate Ventures, Open Field Capital, PTX Capital, Cowen Healthcare Investments, Foresite Capital, Menlo Ventures, OrbiMed, T. Rowe Price Associates, Northpond Ventures, Samsara BioCapital, Rock Springs Capital, AV8 Ventures, Illumina Ventures, Osage University Partners, Windham Venture Partners
|
||||||
01/12/2021 | Series A | $95.97MM | $xx.xx | $170.56MM | OrbiMed, Menlo Ventures, Samsara Biocapital, Illumina Ventures, AV8 Ventures, Windham Venture Partners, Foresite Capital, Northpond Ventures, Cowen Healthcare Investments, Rock Springs Capital, T. Rowe Price Associates | |
Price per Share
$xx.xx
Shares Outstanding
46,272,896
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
OrbiMed, Menlo Ventures, Samsara Biocapital, Illumina Ventures, AV8 Ventures, Windham Venture Partners, Foresite Capital, Northpond Ventures, Cowen Healthcare Investments, Rock Springs Capital, T. Rowe Price Associates
|
||||||
08/12/2019 | Series Seed | $5.5MM | $xx.xx | $11MM | Undisclosed Investors | |
Price per Share
$xx.xx
Shares Outstanding
7,180,334
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Undisclosed Investors
|